PL
EN
Our pipeline & portfolio
At Polpharma Biologics we are focused on developing the next generation of biosimilars to improve patient access and reduce health care costs. Our pipeline is continuously growing and our late stage products are nearing the market. We look to partner with some of the worlds largest biotech so our biosimilars can reach those that need them.
Polpharma Biologics, an international biotech company dedicated to the development and manufacturing of biosimilars,...
Polpharma Biologics, an international biotech company dedicated to the development and manufacture of biosimilars, an...
Polpharma Biologics today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Me...
Amsterdam Munich, Zug – Polpharma Biologics Group BV (“Polpharma Biologics”), Formycon AG (“Formycon”) and Bioeq AG (...
Polpharma Biologics Group BV (“Polpharma Biologics”), Formycon AG (“Formycon”) and Bioeq AG (“Bioeq”), jointly announ...
Polpharma Biologics announced today that the U.S. Food and Drug Administration (FDA) has accepted the first-ever Biol...